Investigational drug · Phase 2
HRS-9813
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors, IPF and PPF.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "HRS-9813"
First trial start
2024
Aug 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-9813", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Unresectable or Metastatic Breast Cancer
- Advanced Solid Tumors
- IPF and PPF
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-9813" as an intervention, largest first.
- A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid TumorsPivotal-lookingRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06555068 · 528 participants (planned) · Start Aug 12, 2024 · Primary completion Dec 2027
Drug: HRS-6209 in Combination with Fulvestrant; HRS-6209 in Combination with HRS-1358 and 9 more · For: Advanced Unresectable or Metastatic Breast Cancer; Advanced Solid Tumors
Sites: Shanghai, China
- Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary FibrosisPivotal-lookingRecruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07192939 · 270 participants (planned) · Start Oct 29, 2025 · Primary completion Jun 2028
Drug: HRS-9813 capsules; HRS-9813 capsules and 1 more · For: IPF and PPF
Sites: Beijing, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06514963 · 50 participants · Start Jul 24, 2024 · Primary completion Jan 2, 2025
Drug: HRS-9813; Placebo · For: Healthy Volunteers
Sites: Wuhan, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06821464 · 45 participants · Start Feb 17, 2025 · Primary completion Jul 27, 2025
Drug: HRS-9813; HRS-9813 · For: Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis
Sites: Shanghai, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07229716 · 20 participants · Start Apr 4, 2026 · Primary completion Jun 18, 2026
Drug: HRS-9813 Capsule; Nintedanib Soft Capsules and 1 more · For: Pulmonary Fibrosis
Sites: Xi’an, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06939504 · 12 participants · Start May 4, 2025 · Primary completion Jun 3, 2025
Drug: HRS-9813 Capsule; HRS-9813 Tablet · For: Pulmonary Fibrosis
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Unresectable or Metastatic Breast Cancer
- HRS-6209Phase 35 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Breast Cancer, Advanced Unresectable or Metastatic Breast Cancer of Adults
- HRS-2189Phase 23 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Breast Cancer, Prostate Cancer
- HRS-1358Phase 22 trials
Shandong Suncadia Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors
- FluvustatPhase 21 trial
Shandong Suncadia Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.